Ching-Hsien Chen

Ching-Hsien Chen

Position Title
Assistant Professor

Department of Internal Medicine, School of Medicine

6310 GBSF

Research Interests

Targeting aberrant cell signaling and metabolic reprogramming

Dr. Chen’s research includes: 1) Discovering potential therapeutic targets in both neoplastic and fibrotic diseases using integrated -omics data, genetic manipulation and pharmacological approaches; 2) Developing peptide-based therapeutics to mitigate cancer metastasis and drug resistance by targeting aberrant oncogenic signaling.

Grad Group Affiliations

  • Biochemistry, Molecular, Cellular and Developmental Biology
  • Graduate Group in Integrative Pathobiology
  • Molecular, Cellular and Integrative Physiology

Specialties / Focus

  • Cancer Biology
  • Cell Biology
  • Signal Transduction      


  • PTX202  Principles of Pharmacology and Toxicology (Signaling in Cell Death)

Honors and Awards

  • Outstanding Poster Award, The 2nd Annual UC Davis Kidney Research Symposium, 2017
  • ASN Kidney Week Travel Award, The American Society of Nephrology, 2016
  • Award for Excellence in Postdoctoral Research (Nominee), UC Davis, CA, 2015
  • TRDRP Postdoctoral Fellowship Award, 2014
  • 2014 The Department of Internal Medicine Trainee Research Award, UC Davis, CA, 2014
  • Phil Thai Memorial Award, 5th Annual Lung Research Symposium, UC Davis, CA, 2014
  • 2013 The Department of Internal Medicine Trainee Research Award, UC Davis, CA, 2013

    Professional Societies

    • American Association for Cancer Research
    • American Society of Clinical Oncology
    • American Society of Nephrology
    • American Thoracic Society


    • Ph.D., National Chung Hsing University, Taichung, Taiwan 
    • M.S., China Medical University, Taichung, Taiwan 
    • B.S., China Medical University, Taichung, Taiwan 


    Select Recent Publications

    1. Chen CH, Lin H, Chuang SM, Lin SY, Chen JJW (2010). Acidic stress facilitates tyrosine phosphorylation of HLJ1 to associate with actin cytoskeleton in lung cancer cells. Exp Cell Res, 316:2910-21. PMID: 20615403
    2. Chen CH, Yang MF, Liao JW, Yu SL, Chen JJW (2012). A Novel Function of YWHAZ/β-catenin Axis in Promoting Epithelial-Mesenchymal Transition and Lung Cancer Metastasis. Mol Cancer Res., 10(10):1319-31. PMID: 22912335
    3. Thai P, Statt S, Chen CH, Liang E, Campbell C, Wu R (2013). Characterization of a Novel Long Non-Coding RNA, SCAL1, Induced by Cigarette Smoke and Elevated in Lung Cancer Cell Lines. Am J Respir Cell Mol Biol., 49(2):204-11. PMID: 23672216. PMCID: PMC3824039
    4. Chen CH, Thai P, Yoneda K, Adler KB, Yang PC and Wu R (2014). A peptide that inhibits function of Myristoylated Alanine - Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis. Oncogene, 10; 33(28):3696-706. PMID: 23955080. PMCID: PMC4631387
    5. Chen CH, Chiu CL, Adler KB and Wu R (2014). A novel predictor of cancer malignancy: Up-regulation of MARCKS phosphorylation in lung cancer. Am. J. Respir. Crit. Care Medicine, 189(8):1002-4. PMID: 24735036. PMCID: PMC4098099
    6. Chen CH, Statt S, Chiu CL, Thai P, Arif M, Adler KB, and Wu R (2014). Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications. Am. J. Respir. Crit. Care Medicine, 190(10):1127-38. PMID: 25318062. PMCID: PMC4299640 **Special editorial commentary on article in issue
    7.  Chen CH, Cheng CT, Yuan Y, Zhai J, Arif M, Fong LW, Wu R and Ann DK (2015). Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment. Oncotarget, 20;6(17):15194-208. PMID: 26015406. PMCID: PMC4558145
    8. Chen CH, Chang WH, Su KY, Ku WH, Chang GC, Hong QS, Hsiao YJ, Chen HC, Chen HY, Wu R, Yang PC, Chen JJW, Yu SL (2016). HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms. Oncogene, 35(43):5674-5685. PMID: 27065329
    9. Aboud OA, Chen CH, Senapedis B, Baloglu E, Argueta C, Weiss RH (2016). Dual and specific inhibition of NAMPT and PAK4 by KPT-9274 decreases kidney cancer growth. Mol Cancer Ther., 15(9):2119-2129. PMID: 27390344. PMCID: PMC501093
    10. Chen CH and Weiss RH (2017). GHetting to know ADPKD proliferative signaling, STAT. Kidney Int., 91(3):524-526. PMID: 28202165
    11. Chen CH*, Fong LW, Yu E, Wu R, Trott JF, Weiss RH* (2017). Up-regulation of MARCKS in kidney cancer and its potential as a therapeutic target. Oncogene, 36(25):3588-3598. PMID: 28166200
    12. Fong LWR, Yang DC, Chen CH* (2017). Myristoylated alanine-rich C kinase substrate (MARCKS): a multirole signaling protein in cancers. Cancer metastasis reviews. Cancer metastasis reviews, 36(4):737-747. PMID: 29039083
    13. Chang WH, Thai P, Xu J, Yang DC, Wu R, Chen CH* (2017). Cigarette Smoke Regulates the Competitive Interactions between NRF2 and BACH1 for Heme Oxygenase-1 Induction. Int J Mol Sci. 18(11). PMID: 29125538. PMCID: PMC5713355
    14. Yang DC and Chen CH* (2018). Cigarette Smoking-Mediated Macrophage Reprogramming: Mechanistic Insights and Therapeutic Implications. J Nat Sci. 4(11). PMID: 30801020. PMCID: PMC6383770
    15. Xu J, Chang WH, Fong LW, Weiss RH, Yu SL, Chen CH* (2019). Targeting the insulin-like growth factor-1 receptor in MTAP-deficient renal cell carcinoma. Signal Transduct Target Ther. 4:2. PMID: 30701095. PMCID: PMC6345872   

    Complete List of Published Work in My Bibliography: